Literature DB >> 10155303

Societal perspective on the burden of migraine in The Netherlands.

L van Roijen1, M L Essink-Bot, M A Koopmanschap, B C Michel, F F Rutten.   

Abstract

This study presents a comprehensive overview of the societal burden of migraine in The Netherlands. We assessed the direct and indirect costs of this disease, and the health status of patients with migraine. We developed the 'illness and labour' (I&L) questionnaire to collect data on the effect of illness on labour performance. 846 migraine patients and 834 controls were selected from the general population. Participants completed an I&L questionnaire as well as generic health status questionnaires. The direct costs of migraine amounted to 134 million Netherlands guilders (NLG) [$US1 = NLG1.68, October 1994]. Conservative calculations of the costs of absence from work and reduced productivity at work were NLG264 and NLG277 million per year, respectively. Our study did not indicate that migraine caused household productivity losses. The baseline estimate of the total societal costs of migraine in The Netherlands was NLG675 million per year. The assessment of health status showed considerable impairment of psychological and social functioning in migraine patients.

Entities:  

Mesh:

Year:  1995        PMID: 10155303     DOI: 10.2165/00019053-199507020-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

2.  Cost of illness studies: no aid to decision making: Reply to Shiell et al. (Health Policy, 8 (1987) 317-323).

Authors:  C Behrens; K Henke
Journal:  Health Policy       Date:  1988-10       Impact factor: 2.980

3.  Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323).

Authors:  T A Hodgson
Journal:  Health Policy       Date:  1989       Impact factor: 2.980

4.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

5.  A survey of migraine in England 1975-1976.

Authors:  J E Green
Journal:  Headache       Date:  1977-05       Impact factor: 5.887

6.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

7.  The epidemiological enigma of migraine.

Authors:  W E Waters
Journal:  Int J Epidemiol       Date:  1973       Impact factor: 7.196

8.  Towards a definition of migraine headache.

Authors:  J N Blau
Journal:  Lancet       Date:  1984-02-25       Impact factor: 79.321

9.  Grading the severity of chronic pain.

Authors:  Michael Von Korff; Johan Ormel; Francis J Keefe; Samuel F Dworkin
Journal:  Pain       Date:  1992-08       Impact factor: 6.961

10.  [The cost of illness].

Authors:  L van Roijen; M A Koopmanschap; L Bonneux
Journal:  Ned Tijdschr Geneeskd       Date:  1992-01-11
View more
  20 in total

Review 1.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

Authors:  L M Bloudek; M Stokes; D C Buse; T K Wilcox; R B Lipton; P J Goadsby; S F Varon; A M Blumenfeld; Z Katsarava; J Pascual; M Lanteri-Minet; P Cortelli; P Martelletti
Journal:  J Headache Pain       Date:  2012-05-29       Impact factor: 7.277

Review 3.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

5.  A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.

Authors:  P Cortelli; C Dahlöf; J Bouchard; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

Review 6.  Burden of migraine. A review of its socioeconomic impact.

Authors:  G D Solomon; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

7.  Treatment of migraine and tension-type headache in Croatia.

Authors:  Vlasta Vuković; Davor Plavec; Arijana Lovrencić Huzjan; Mislav Budisić; Vida Demarin
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

8.  Effectiveness of eletriptan in reducing time loss caused by migraine attacks.

Authors:  N E Wells; T J Steiner
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

9.  Reductions in individual work productivity associated with type 2 diabetes mellitus.

Authors:  Jill E Lavigne; Charles E Phelps; Alvin Mushlin; Wayne M Lednar
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.

Authors:  André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.